《績後表現》石藥(01093.HK)全年多賺21%增派息兼建議送紅股 午後股價曾升逾3%高見16.76元
藍籌石藥(01093.HK)去年多賺21%增派息兼建議送紅股,該股承半日逆市倒升1.8%重越20天線(16.4元)勢,午後曾抽升3.2%至16.76元,現造16.68元,逆市回升2.7%,成交1,188萬股,涉資1.94億元。
石藥中午公布,去年純利按年升20.6%至37.14億元人民幣(下同),每股盈利59.65分,末期股息按11%至20港仙,另再建議5股逆1股紅股,惟須待股東大會批准才作實。期內,毛利按年升35.6%至159.1億元;經營溢利按年升逾20%至46億元,總營收按年升近25%至221.03億元。
恆指午後跌幅進一步收窄至151點或0.6%,報23,332,成交額612億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.